[New developments in X-PAP therapy for obstructive and central sleep-disordered breathing] [0.03%]
新型X-PAP疗法在阻塞性和中枢性睡眠呼吸障碍中应用的新进展
K-H Rühle,K J Franke,U Domanski et al.
K-H Rühle et al.
[The iron lung] [0.03%]
【铁肺】
R Kropp
R Kropp
K Kambartel,A Filipiak,H Hüschen et al.
K Kambartel et al.
There are different tools for the removal of endobronchial foreign bodies. The Roth-Net® is a further development of the Dormia basket. It enables an easy and sure retraction of a foreign body from the bronchial system. This will be presen...
S Ewig,T Schaberg
S Ewig
H Hof
H Hof
As typical opportunistic pathogens fungi, for example Pneumocystis jirovecii, infect predominantly immunocompromised hosts. There are, however, others, for example Coccidioides immitis and Cryptococcus neoformans, which endanger otherwise h...
[Importance of lung function for pulmonary hypertension in sarcoidosis] [0.03%]
[肺功能在肺泡蛋白沉积症合并肺动脉高压中的意义]
M Held,D Jonas-Klemm,B H Jany
M Held
Background: The reported prevalence of pulmonary hypertension (PH) in sarcoidosis is variable and depends on the ethnic background, the underlying pathophysiology and the diagnostic methods used. We aimed to analyse the p...
[Employing tyrosine kinase inhibitors in the first line treatment of EGFR-positive metastatic NSCLC - state of the art and recent developments] [0.03%]
【表皮生长因子受体阳性转移性非小细胞肺癌一线治疗中酪氨酸激酶抑制剂的最新进展】
R Wiewrodt,M Serke,C Grohé et al.
R Wiewrodt et al.
In this review article we present an overview of recent developments in EGFR TKIs in lung cancer therapy. Besides the approved drugs erlotinib and gefitinib, clinical data on second-generation irreversible TKIs including afatinib, dacomitin...
[Expert meeting chronic obstructive airway disease--cardiovascular aspects of COPD] [0.03%]
慢性阻塞性肺病的心血管问题专家讨论会
J Lorenz,R Bals,H Magnussen et al.
J Lorenz et al.
This overview presents data that take advantage of a new step of insight into COPD. Large population-based retrospective studies and intensively investigated prospective cohorts are two important sources of knowledge that have been recently...
[Prospective evaluation of clinical parameters of AAT patients with i. v. prolastin therapy in a homecare setting] [0.03%]
经静脉注射Prolastin治疗的α1-抗胰蛋白酶缺乏患者在家访条件下的临床参数评估
A Wilke,C Grohé
A Wilke
Prognostic parameters and indicators of deterioration of prolastin substituted alpha 1 antitrypsin deficient COPD (AAT) are poorly defined. In particular, there is a lack of information how patients with AAT report exacerbations or how intr...